Safety and efficacy of human umbilical cord-derived mesenchymal stem cells in COVID-19 patients: A real-world observation DOI Creative Commons
Siyu Wang, Tao Yang, Tiantian Li

и другие.

Chinese Medical Journal, Год журнала: 2025, Номер unknown

Опубликована: Март 7, 2025

The effects of human umbilical cord-derived mesenchymal stem cell (UC-MSC) treatment on coronavirus disease 2019 (COVID-19) patients have been preliminarily characterized. However, real-world data the safety and efficacy intravenous transfusions MSCs in hospitalized COVID-19 at convalescent stage remain to be reported. This was a single-arm, multicenter, real-word study which contemporaneous external control included as group. Besides, severe critical were considered together group, given small number patients. For total 110 patients, 21 moderate 31 enrolled MSC while 26 32 All received standard treatment. infusions dose 4 × 107 cells days 0, 3, 6, respectively. clinical outcomes, including adverse events (AEs), lung lesion proportion chest computed tomography, pulmonary function, 6-min walking distance (6-MWD), symptoms, laboratory parameters, measured 28, 90, 180, 270, 360 during follow-up visits. In with COVID-19, improved function forced expiratory volume first second (FEV1) maximum vital capacity (VCmax) 28 (FEV1, 2.75 [2.35, 3.23] v.s 2.11 [1.96, 2.35], P = 0.008; VCmax, 2.92 [2.55, 3.60] 2.47 [2.18, 2.68], 0.041), 90 2.93 [2.63, 3.27] 2.38 [2.24, 2.63], 0.017; 3.52 [3.02, 3.80] 2.59 [2.45, 3.15], 0.017), 2.91 [2.75, 3.18] 2.30 [2.16, 2.70], 0.019; VCmax,3.61 [3.35, 3.97] 2.69 [2.56, 3.23], 0.036) compared controls. addition, notably reduced ground-glass lesions whole day (P 0.045) No difference incidence AEs observed between two groups. Similarly, no significant differences found 6-MWD, D-dimer levels, or interleukin-6 concentrations Our results demonstrate potential for comprehensive long-term studies are required confirm Chinese Clinical Trial Registry, ChiCTR2000031430.

Язык: Английский

Safety and efficacy of human umbilical cord-derived mesenchymal stem cells in COVID-19 patients: A real-world observation DOI Creative Commons
Siyu Wang, Tao Yang, Tiantian Li

и другие.

Chinese Medical Journal, Год журнала: 2025, Номер unknown

Опубликована: Март 7, 2025

The effects of human umbilical cord-derived mesenchymal stem cell (UC-MSC) treatment on coronavirus disease 2019 (COVID-19) patients have been preliminarily characterized. However, real-world data the safety and efficacy intravenous transfusions MSCs in hospitalized COVID-19 at convalescent stage remain to be reported. This was a single-arm, multicenter, real-word study which contemporaneous external control included as group. Besides, severe critical were considered together group, given small number patients. For total 110 patients, 21 moderate 31 enrolled MSC while 26 32 All received standard treatment. infusions dose 4 × 107 cells days 0, 3, 6, respectively. clinical outcomes, including adverse events (AEs), lung lesion proportion chest computed tomography, pulmonary function, 6-min walking distance (6-MWD), symptoms, laboratory parameters, measured 28, 90, 180, 270, 360 during follow-up visits. In with COVID-19, improved function forced expiratory volume first second (FEV1) maximum vital capacity (VCmax) 28 (FEV1, 2.75 [2.35, 3.23] v.s 2.11 [1.96, 2.35], P = 0.008; VCmax, 2.92 [2.55, 3.60] 2.47 [2.18, 2.68], 0.041), 90 2.93 [2.63, 3.27] 2.38 [2.24, 2.63], 0.017; 3.52 [3.02, 3.80] 2.59 [2.45, 3.15], 0.017), 2.91 [2.75, 3.18] 2.30 [2.16, 2.70], 0.019; VCmax,3.61 [3.35, 3.97] 2.69 [2.56, 3.23], 0.036) compared controls. addition, notably reduced ground-glass lesions whole day (P 0.045) No difference incidence AEs observed between two groups. Similarly, no significant differences found 6-MWD, D-dimer levels, or interleukin-6 concentrations Our results demonstrate potential for comprehensive long-term studies are required confirm Chinese Clinical Trial Registry, ChiCTR2000031430.

Язык: Английский

Процитировано

1